Casadevall N
Laboratoire d'Hématologie, Hôpital Raymond Poincaré, Garches, France.
Nouv Rev Fr Hematol (1978). 1994 Apr;36(2):173-6.
In vivo and in vitro bioassays, radio immunoassays (RIA), enzyme linked immunoassays (ELISA) and immunoradiometric assays (IRMA) have been applied to measure serum erythropoietin (Epo) levels. Results are expressed in international units (IU). In vivo bioassays are time consuming, expensive and not sensitive enough to measure the amount of Epo in normal sera. Nevertheless, this test remains the standard of comparison for the other new assays. Immunologic technics are specific, sensitive, reproducible, easy to perform, rapid and are now preferred for the measurement of Epo. Published values for non anemic human range from 6 to 32 IU/l. In the search of etiology of a polycythemia, the results of usual investigations to class the polycythemia either as primitive (P. vera) or secondary are often inconclusive. In these situations, measurement of serum Epo could be of value for accurate a differential diagnosis. However the results of the literature and our personal experience, show that the serum Epo level does not discriminate with an absolute fiability between Polycythemia Vera and secondary polycythemia because of a great overlap between the two groups.
体内和体外生物测定、放射免疫测定（RIA）、酶联免疫吸附测定（ELISA）和免疫放射测定（IRMA）已被用于测量血清促红细胞生成素（Epo）水平。结果以国际单位（IU）表示。体内生物测定耗时、昂贵，且对测量正常血清中的Epo量不够敏感。尽管如此，该测试仍是其他新测定方法的比较标准。免疫技术具有特异性、敏感性、可重复性、易于操作、快速，现在是测量Epo的首选方法。非贫血人类的公布值范围为6至32 IU/l。在寻找真性红细胞增多症的病因时，将真性红细胞增多症归类为原发性（真性红细胞增多症）或继发性的常规检查结果往往没有定论。在这些情况下，测量血清Epo可能有助于准确进行鉴别诊断。然而，文献结果和我们的个人经验表明，由于两组之间存在很大重叠，血清Epo水平并不能绝对可靠地区分真性红细胞增多症和继发性红细胞增多症。
